Kodiak Sciences Inc (KOD)vsRoyalty Pharma Plc (RPRX)
KOD
Kodiak Sciences Inc
$43.40
-4.34%
HEALTHCARE · Cap: $2.49B
RPRX
Royalty Pharma Plc
$57.97
+2.11%
HEALTHCARE · Cap: $33.65B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
KOD
Avoid25
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KOD.
Margin of Safety
-61.3%
Fair Value
$35.20
Current Price
$57.97
$22.77 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Generating 1.4B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : KOD
KOD has a balanced fundamental profile.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : KOD
The primary concerns for KOD are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
KOD profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
KOD carries more volatility with a beta of 2.21 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 25/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kodiak Sciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?